ID18741A - Zat nikotinat dalam terapi - Google Patents

Zat nikotinat dalam terapi

Info

Publication number
ID18741A
ID18741A IDP973538A ID973538A ID18741A ID 18741 A ID18741 A ID 18741A ID P973538 A IDP973538 A ID P973538A ID 973538 A ID973538 A ID 973538A ID 18741 A ID18741 A ID 18741A
Authority
ID
Indonesia
Prior art keywords
nicotinic
therapy
substance
nicotinic substance
Prior art date
Application number
IDP973538A
Other languages
English (en)
Indonesian (id)
Inventor
Brian Thomas O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID18741A publication Critical patent/ID18741A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IDP973538A 1996-10-30 1997-10-28 Zat nikotinat dalam terapi ID18741A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2880496P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
ID18741A true ID18741A (id) 1998-05-07

Family

ID=21845528

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP973538A ID18741A (id) 1996-10-30 1997-10-28 Zat nikotinat dalam terapi

Country Status (17)

Country Link
US (2) US6235734B1 (fr)
EP (1) EP0937077B1 (fr)
JP (2) JP3621707B2 (fr)
AP (1) AP9701125A0 (fr)
AR (1) AR008901A1 (fr)
AT (1) ATE326468T1 (fr)
AU (1) AU4394897A (fr)
DE (1) DE69735891T2 (fr)
ES (1) ES2264169T3 (fr)
GT (1) GT199700115A (fr)
HR (1) HRP970567A2 (fr)
ID (1) ID18741A (fr)
MA (1) MA26445A1 (fr)
PA (1) PA8440201A1 (fr)
TN (1) TNSN97168A1 (fr)
WO (1) WO1998018798A1 (fr)
ZA (1) ZA979706B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE60228478D1 (de) 2001-11-30 2008-10-02 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2005000806A2 (fr) * 2003-06-10 2005-01-06 Georgetown University Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands
EP1648893B1 (fr) 2003-07-21 2009-09-23 Pfizer Products Inc. Composes azapolycycliques fusionnes avec heteroaryle pour reduire la dependance a la nicotine
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
US7135933B2 (en) * 2004-09-29 2006-11-14 Intelliserv, Inc. System for adjusting frequency of electrical output pulses derived from an oscillator
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007100430A2 (fr) * 2006-01-27 2007-09-07 Yale University Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
WO2007115092A2 (fr) * 2006-03-29 2007-10-11 Georgetown University Dérivés de cytisine substitués en position 10 et leurs procédés d'utilisation
US7404725B2 (en) * 2006-07-03 2008-07-29 Hall David R Wiper for tool string direct electrical connection
US8061443B2 (en) * 2008-04-24 2011-11-22 Schlumberger Technology Corporation Downhole sample rate system
MX368365B (es) * 2009-12-22 2019-09-30 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
AU2017313390A1 (en) * 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction
JP7178158B2 (ja) 2017-07-24 2022-11-25 アチーブ ファーマ ユーケイ リミテッド シチシン塩、シチシン塩の溶媒和物または水和物、シチシン塩の製造方法、医薬組成物、および治療方法
CN114727647A (zh) * 2019-09-12 2022-07-08 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3332429T1 (de) * 1982-02-22 1984-01-26 Belorusskij naučno-issledovatel'skij sanitarno-gigieničeskij institut, 220012 Minsk Arzneipraeparat mit antinikotinwirkung und verfahren zu seiner herstellung
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
TW261531B (fr) * 1993-10-28 1995-11-01 Dynagen Inc
WO1997011072A1 (fr) * 1995-09-22 1997-03-27 Novo Nordisk A/S Nouveaux composes azacycliques ou azabicycliques a substitution

Also Published As

Publication number Publication date
ZA979706B (en) 1999-04-29
EP0937077A1 (fr) 1999-08-25
JP2000505809A (ja) 2000-05-16
EP0937077B1 (fr) 2006-05-17
JP3621707B2 (ja) 2005-02-16
HRP970567A2 (en) 1998-10-31
US6235734B1 (en) 2001-05-22
ATE326468T1 (de) 2006-06-15
AP9701125A0 (en) 1997-10-31
AU4394897A (en) 1998-05-22
MA26445A1 (fr) 2004-12-20
WO1998018798A1 (fr) 1998-05-07
PA8440201A1 (es) 2000-05-24
US20030065173A1 (en) 2003-04-03
JP2005060403A (ja) 2005-03-10
DE69735891D1 (de) 2006-06-22
AR008901A1 (es) 2000-02-23
TNSN97168A1 (fr) 2005-03-15
ES2264169T3 (es) 2006-12-16
US6630467B2 (en) 2003-10-07
GT199700115A (es) 1999-04-20
DE69735891T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ID18741A (id) Zat nikotinat dalam terapi
NO983560D0 (no) Triazolderivater nyttige i terapi
ID17948A (id) Piridine bersumbu heterosiklik
BR9612263A (pt) Compostos quinolina e qinazolina úteis em terapia
FI970762A (fi) Terapiassa käyttökelpoiset spiroatsabisykliset yhdisteet
PT869126E (pt) Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos
TR199501305A2 (tr) Heterosiklik bilesikler ve bunlarin hazirlanmasi ve kullanimi
EE9800042A (et) Inhalaatorites kasutatav seade
NO982435D0 (no) Blodoppvarmingsapparat
EE03439B1 (et) Teraapias kasutatavad bitsüklilised isotiokarbamiidi derivaadid
DE59710593D1 (de) Therapiegerät
NO964541L (no) Porphacyanin og CNC-utvidete porphyriner
DE59711085D1 (de) Therapiegerät
DK0826679T3 (da) Naphthylforbindelser og -præparater
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
ID16978A (id) Zat pelindung kulit
DE69634991D1 (de) Elektrotherapiegerät
SE9602645D0 (sv) Azabicyclic derivatives useful in therapy
BR7601811U (pt) Disposição introduzida em fralda
BR7400430U (pt) Disposição introduzida em guarda-roupa
BR9700076A (pt) Aperfeiçoamento introduzido em prótese cardáica
BR7601750U (pt) Disposição introduzida em semeadeira
BR7400422U (pt) Disposição introduzida em guarda-sol
BR7602255U (pt) Disposição introduzida em cobertura
EE00130U1 (et) Muda-parafiinimarlis